Correction: Amphiregulin enhances alpha6beta1 integrin expression and cell motility in human chondrosarcoma cells through Ras/Raf/MEK/ERK/AP-1 pathway
Metrics: PDF 1892 views | ?
Present: Due to an error during figure assembly, Figure 4C mistakenly contains the same image as Figure 3D.
Correct: The proper Figure 4C is shown below. The authors sincerely apologize for this oversight. The conclusions of the paper remain unchanged.
Original article: Oncotarget. 2015; 6(13):11434-46. DOI: 10.18632/oncotarget.3397
Figure 4: Activation of c-Jun is required for AR-induced cell migration and up-regulation of integrin α6β1. A. Cells were incubated with AR (50 ng/ml) for indicated time intervals. The phosphorylation status and total levels of c-Jun were measured by Western blot. B. Cells pretreated with manumycin A, GW5074, PD98059, or U0126 for 30 min followed by treatment with AR (50 ng/ml) for 15 min. The levels of p-c-Jun and c-Jun were measured by Western blot. C-G. Cells were pretreated with curcumin (10 μM) or tanshinone (10 μM) for 30 min or transfected with c-Jun siRNA for 24 h followed by stimulation with AR (50 ng/ml) for 24 h. The knockdown effciency was veri ed by Western blot. The in vitro migration was measured by Transwell assay (C-D) The expression of integrin α6β1 was measured by q-PCR (E-F) and ow cytometry (G). H. Cells were pretreated with manumycin A, GW5074, PD98059, or U0126 for 30 min, followed by stimulation with AR (50 ng/ml), and chromatin immunoprecipitation assay was then performed. Chromatin was immunoprecipitated with anti-c-Jun antibody. One percent of the precipitated chromatin was assayed to verify equal loading (input). I. Cells pretreated with manumycin A, GW5074, PD98059, or U0126, followed by stimulation with AR (50 ng/ml) for 24 h. Equal amounts of cell extract were assayed for dual-luciferase activity. Results are expressed as mean ± SEM. *P < 0.05 compared with control; #P < 0.05 compared with AR-treated group.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.